Biologic Treatment of Severe Asthma / 대한내과학회지
Korean Journal of Medicine
;
: 172-180, 2018.
Artículo
en Coreano
| WPRIM
| ID: wpr-713793
ABSTRACT
Beyond the existing scope of asthma treatment, a number of biologics have recently been developed based on the immunopathological mechanism of severe asthma. Severe asthma has a wide variety of phenotypes or endotypes, more than half of which are associated with eosinophils or type 2 inflammation. This paper introduces newly developed biologics and those that are under development for treatment of asthma. The most successful biologics developed to date are anti-IgE and anti-interleukin (IL)-5 antibodies, followed by anti-IL-4, anti-IL-13, anti-prostaglandin D2 type 2 receptor, and anti-thymic stromal lymphopoietin antibodies. However, further studies on drugs that target type 1 inflammation are required.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Fenotipo
/
Asma
/
Estado Asmático
/
Productos Biológicos
/
Terapia Biológica
/
Eosinófilos
/
Inflamación
/
Anticuerpos
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS